As investors fret about Xyrem durability, Jazz spends $52M+ upfront to swallow neuro-focused biotech

With investors getting jittery about the durability of Jazz Pharma’s cash-cow Xyrem, the specialty biopharmaceutical drugmaker is expanding its portfolio with the purchase of Cavion, a biotechnology company focused on rare, chronic neurological diseases.